Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

10x Genomics (TXG) Cost of Revenue (2018 - 2026)

10x Genomics' Cost of Revenue history spans 8 years, with the latest figure at $53.0 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 2.0% to $53.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $198.9 million, a 1.34% increase, with the full-year FY2025 number at $198.9 million, up 1.34% from a year prior.
  • Cost of Revenue hit $53.0 million in Q4 2025 for 10x Genomics, up from $48.7 million in the prior quarter.
  • Over the last five years, Cost of Revenue for TXG hit a ceiling of $68.2 million in Q4 2023 and a floor of $4.9 million in Q2 2021.
  • Historically, Cost of Revenue has averaged $40.0 million across 5 years, with a median of $46.2 million in 2023.
  • Biggest five-year swings in Cost of Revenue: tumbled 51.1% in 2021 and later surged 463.66% in 2022.
  • Tracing TXG's Cost of Revenue over 5 years: stood at $27.6 million in 2021, then skyrocketed by 33.44% to $36.8 million in 2022, then skyrocketed by 85.18% to $68.2 million in 2023, then dropped by 20.72% to $54.1 million in 2024, then decreased by 2.0% to $53.0 million in 2025.
  • Business Quant data shows Cost of Revenue for TXG at $53.0 million in Q4 2025, $48.7 million in Q3 2025, and $47.8 million in Q2 2025.